Comparison · NCT02766335-sae
Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) vs Arm II (Docetaxel - Closed to Accrual 4/2015): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) vs Arm II (Docetaxel - Closed to Accrual 4/2015): serious adverse events. Trial comparisons, record NCT02766335-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02766335-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.397 | 0.289 | 0.516 | wilson | |
| Risk in group 2 | 0.1 | 0.0346 | 0.256 | wilson | |
| Risk difference, group 1 minus group 2 | 0.297 | 0.107 | 0.433 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.97 | 1.3 | 12.1 | log | |
| Odds ratio, group 1 over group 2 | 5.93 | 1.63 | 21.5 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) than on Arm II (Docetaxel - Closed to Accrual 4/2015) | 3.37 | 2.31 | 9.32 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) | Arm I- Participants receive MEDI4736 (durvalumab) IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.~Arm III-For participants assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, participants may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Participants will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed.~Durvalumab: Given IV~Laboratory Biomarker Analysis: Correlative studies~Arm III~Durvalumab: Given IV~Laboratory Biomarker Analysis: Correlative studies | 27 | 68 | EG000 |
| Group 2 | Arm II (Docetaxel - Closed to Accrual 4/2015) | Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)~Docetaxel: Given IV~Laboratory Biomarker Analysis: Correlative studies | 3 | 30 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Duration of treatment and follow up until death or 3 years post registration
Source ClinicalTrials.gov
Trial
- Title
- Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- NCT number
- NCT02766335
- Phases
- PHASE2, PHASE3
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Durvalumab, Laboratory Biomarker Analysis
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2021-12-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02766335?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02766335-sae